Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency

<p>Abstract</p> <p>Background</p> <p>SLC6A8, an X-linked gene, encodes the creatine transporter (CRTR) and its mutations lead to cerebral creatine (Cr) deficiency which results in mental retardation, speech and language delay, autistic-like behaviour and epilepsy (CRTR-...

Full description

Bibliographic Details
Main Authors: Chilosi Annamaria, Casarano Manuela, Comparini Alessandro, Battaglia Francesca, Mancardi Margherita, Schiaffino Cristina, Tosetti Michela, Leuzzi Vincenzo, Battini Roberta, Cioni Giovanni
Format: Article
Language:English
Published: BMC 2012-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:http://www.ojrd.com/content/7/1/43
id doaj-f38bcee5b2d64cd6b708ba9c5ab5148b
record_format Article
spelling doaj-f38bcee5b2d64cd6b708ba9c5ab5148b2020-11-25T00:20:52ZengBMCOrphanet Journal of Rare Diseases1750-11722012-06-01714310.1186/1750-1172-7-43Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiencyChilosi AnnamariaCasarano ManuelaComparini AlessandroBattaglia FrancescaMancardi MargheritaSchiaffino CristinaTosetti MichelaLeuzzi VincenzoBattini RobertaCioni Giovanni<p>Abstract</p> <p>Background</p> <p>SLC6A8, an X-linked gene, encodes the creatine transporter (CRTR) and its mutations lead to cerebral creatine (Cr) deficiency which results in mental retardation, speech and language delay, autistic-like behaviour and epilepsy (CRTR-D, OMIM 300352). CRTR-D represents the most frequent Cr metabolism disorder but, differently from Cr synthesis defects, that are partially reversible by oral Cr supplementation, does not respond to Cr treatment even if precociously administrated. The precursors of Cr are the non-essential amino acids Glycine (Gly) and Arginine (Arg), which have their own transporters at the brain–blood barrier level and, therefore, their supplementation appears an attractive and feasible therapeutic option aimed at stimulating Cr endogenous synthesis and, in this way, at overcoming the block of Cr transport within the brain. However, until now the effects of Arg and/or Gly supplementation on Cr brain levels and behaviour have been controversial.</p> <p>Methods</p> <p>In this study five Italian male patients affected by CRTR-D were supplemented with oral L-Arg at a dosage of 300 mg/kg/day divided into 3 doses, for 24–36 months. Biochemical and plasmatic amino acids examinations and thyroid hormone dosages were periodically performed. Moreover, Proton and Phosphorus Magnetic Resonance Spectroscopy (MRS) was monitored during follow-up in concurrence with neuropsychological evaluations.</p> <p>Results</p> <p>During L-Arg treatment a clinical improvement in motor skills and to a lesser extent in communication and attention was observed. In addition, all patients had a reduction in the number and frequency of epileptic seizures. Daily living skills appeared also to be positively influenced by L-Arg treatment. Moreover, Total Cr and especially PhosphoCr, evaluated by proton and phosphorus spectroscopy, showed a mild increase, although well below the normal range.</p> <p>Conclusion</p> <p>This study provides information to support the effectiveness of L-Arg supplement treatment in CTRT-D patients; in fact the syndromic pattern of cognitive and linguistic deficit presented by CRTR-D patients was partially altered by L-Arg supplementation especially at a qualitative clinical level. Oral L-Arg may represent not only a protective factor towards a further cognitive decline, but can lead to the acquisition of new skills.</p> http://www.ojrd.com/content/7/1/43Creatine transporter deficiencyXLMRSpeech delayArginine treatment<it>SLC6A8</it> geneMagnetic resonance spectroscopy
collection DOAJ
language English
format Article
sources DOAJ
author Chilosi Annamaria
Casarano Manuela
Comparini Alessandro
Battaglia Francesca
Mancardi Margherita
Schiaffino Cristina
Tosetti Michela
Leuzzi Vincenzo
Battini Roberta
Cioni Giovanni
spellingShingle Chilosi Annamaria
Casarano Manuela
Comparini Alessandro
Battaglia Francesca
Mancardi Margherita
Schiaffino Cristina
Tosetti Michela
Leuzzi Vincenzo
Battini Roberta
Cioni Giovanni
Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
Orphanet Journal of Rare Diseases
Creatine transporter deficiency
XLMR
Speech delay
Arginine treatment
<it>SLC6A8</it> gene
Magnetic resonance spectroscopy
author_facet Chilosi Annamaria
Casarano Manuela
Comparini Alessandro
Battaglia Francesca
Mancardi Margherita
Schiaffino Cristina
Tosetti Michela
Leuzzi Vincenzo
Battini Roberta
Cioni Giovanni
author_sort Chilosi Annamaria
title Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
title_short Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
title_full Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
title_fullStr Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
title_full_unstemmed Neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
title_sort neuropsychological profile and clinical effects of arginine treatment in children with creatine transport deficiency
publisher BMC
series Orphanet Journal of Rare Diseases
issn 1750-1172
publishDate 2012-06-01
description <p>Abstract</p> <p>Background</p> <p>SLC6A8, an X-linked gene, encodes the creatine transporter (CRTR) and its mutations lead to cerebral creatine (Cr) deficiency which results in mental retardation, speech and language delay, autistic-like behaviour and epilepsy (CRTR-D, OMIM 300352). CRTR-D represents the most frequent Cr metabolism disorder but, differently from Cr synthesis defects, that are partially reversible by oral Cr supplementation, does not respond to Cr treatment even if precociously administrated. The precursors of Cr are the non-essential amino acids Glycine (Gly) and Arginine (Arg), which have their own transporters at the brain–blood barrier level and, therefore, their supplementation appears an attractive and feasible therapeutic option aimed at stimulating Cr endogenous synthesis and, in this way, at overcoming the block of Cr transport within the brain. However, until now the effects of Arg and/or Gly supplementation on Cr brain levels and behaviour have been controversial.</p> <p>Methods</p> <p>In this study five Italian male patients affected by CRTR-D were supplemented with oral L-Arg at a dosage of 300 mg/kg/day divided into 3 doses, for 24–36 months. Biochemical and plasmatic amino acids examinations and thyroid hormone dosages were periodically performed. Moreover, Proton and Phosphorus Magnetic Resonance Spectroscopy (MRS) was monitored during follow-up in concurrence with neuropsychological evaluations.</p> <p>Results</p> <p>During L-Arg treatment a clinical improvement in motor skills and to a lesser extent in communication and attention was observed. In addition, all patients had a reduction in the number and frequency of epileptic seizures. Daily living skills appeared also to be positively influenced by L-Arg treatment. Moreover, Total Cr and especially PhosphoCr, evaluated by proton and phosphorus spectroscopy, showed a mild increase, although well below the normal range.</p> <p>Conclusion</p> <p>This study provides information to support the effectiveness of L-Arg supplement treatment in CTRT-D patients; in fact the syndromic pattern of cognitive and linguistic deficit presented by CRTR-D patients was partially altered by L-Arg supplementation especially at a qualitative clinical level. Oral L-Arg may represent not only a protective factor towards a further cognitive decline, but can lead to the acquisition of new skills.</p>
topic Creatine transporter deficiency
XLMR
Speech delay
Arginine treatment
<it>SLC6A8</it> gene
Magnetic resonance spectroscopy
url http://www.ojrd.com/content/7/1/43
work_keys_str_mv AT chilosiannamaria neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT casaranomanuela neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT comparinialessandro neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT battagliafrancesca neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT mancardimargherita neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT schiaffinocristina neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT tosettimichela neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT leuzzivincenzo neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT battiniroberta neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
AT cionigiovanni neuropsychologicalprofileandclinicaleffectsofargininetreatmentinchildrenwithcreatinetransportdeficiency
_version_ 1725365361106223104